Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 8/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 8/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | PARG | Q86W56 | 1/20 | 0.32 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5158301 | 0.95 | ITGB1 (0.50) | ITGB1ITGA4KDM1AMEN1KMT2A | |
| SCHEMBL5161118 | 0.95 | ITGB1 (0.43) | ITGB1ITGA4KDM1AMEN1KMT2A | |
| SCHEMBL5422528 | 0.91 | ITGB1 (0.46) | ITGB1ITGA4KDM1AMEN1KMT2A | |
| SCHEMBL5158240 | 0.89 | ITGB1 (0.48) | ITGB1ITGA4KDM1AMEN1KMT2A | |
| SCHEMBL5176265 | 0.88 | ITGB1 (0.47) | ITGB1ITGA4KDM1AMEN1KMT2A | |
| SCHEMBL5163411 | 0.88 | ITGB1 (0.46) | ITGB1ITGA4KDM1AMEN1KMT2A | |
| SCHEMBL5163393 | 0.88 | ITGB1 (0.43) | ITGB1ITGA4KDM1AMEN1KMT2A | |
| SCHEMBL5160221 | 0.85 | ITGB1 (0.45) | ITGB1ITGA4KDM1AMEN1KMT2A | |
| SCHEMBL5160701 | 0.84 | ITGB1 (0.47) | ITGB1ITGA4KDM1AMEN1KMT2A | |
| SCHEMBL5159930 | 0.83 | ITGA4 (0.53) | ITGB1ITGA4KDM1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | ITGB1 9/4885ITGA4 3/4885KDM1A 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.